🩸 Hematology Headlines You Shouldn’t Miss This Week
Welcome to this week’s Hematology Research Update! This episode dives deep into groundbreaking developments in blood cancers, rare bleeding disorders, and next-gen therapies transforming patient outcomes worldwide.
✨ Here’s what’s inside:
🔬 Daratumumab SC now approved for all newly diagnosed myeloma patients—regardless of transplant eligibility
🧪 Tambiciclib show median overall survival of 8.8 months in relapsed/refractory AML
📦 Ziftomenib NDA submitted—potential first targeted therapy for NPM1-mutant AML
🧠 High-intensity induction achieves greater than 95 percent MRD negativity in high-risk mantle cell lymphoma
🇨🇦 Altuviiio approved in Canada for hemophilia A with once-weekly dosing
🇨🇳 China’s first gene therapy approved for hemophilia B—dramatic reduction in bleed rate
🧲 AFM13-NK cell therapy hits 93 percent overall response in CD30+ lymphomas, with no CRS or neurotoxicity
🧫 Elicera’s CAR-T trial advances after first patient shows complete response
🧠 REC-3565 study launches using AI-discovered MALT1 inhibitor in B-cell lymphoma
🌱 MaaT033 microbiotherapy deemed safe post–stem cell transplant in Phase 2b trial
📢 Stay Ahead in Hematology Research!
✅ Like, share, and subscribe for weekly updates on hematologic malignancies, immunotherapies, and rare blood disorders
#HematologyResearch #CART #GeneTherapy #AML #MultipleMyeloma #Hemophilia #Ziftomenib #Daratumumab #NKCells #BloodCancerUpdates #LucidQuest